Related Experiment Video
Updated: Jul 4, 2026
07:10
Femoral Bone Marrow Aspiration in Live Mice
Published on: July 5, 2014
Differences in bone responses to recombinant human granulocyte colony-stimulating factor between mice and rats
The Journal of Toxicological Sciences
|June 12, 2008
Summary
Mice treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF) did not exhibit bone changes like rats. This suggests a species-specific difference in bone response to rhG-CSF, with mice showing lower reactivity.
Area of Science:
- Pharmacology
- Bone Biology
- Immunology
Background:
- Recombinant human granulocyte colony-stimulating factor (rhG-CSF) previously induced bone changes in rats.
- These changes included accelerated osteoclastic bone resorption and intramembranous ossification.
Purpose of the Study:
- To investigate if rhG-CSF induces similar bone changes in mice as observed in rats.
- To establish a basis for future mechanistic studies of rhG-CSF-induced bone alterations.
Main Methods:
- Mice (4- or 6-week-old) received subcutaneous rhG-CSF (1,000 or 5,000 microg/kg) for 14 or 28 days.
- Femur and tibia were evaluated histopathologically.
- Peripheral blood leukocyte counts, spleen, and bone marrow were assessed.
Main Results:
- rhG-CSF treatment increased leukocyte counts, caused splenomegaly, and increased granulopoietic cells in mice, consistent with G-CSF's known activity.
- Histopathological bone changes, including accelerated osteoclastic resorption and intramembranous ossification, were not detected in mice.
- Mice showed significantly lower reactivity to rhG-CSF treatment compared to rats.
Conclusions:
- A species-related difference exists in the bone response to rhG-CSF between mice and rats.
- Mice exhibit lower reactivity to rhG-CSF-induced bone changes than rats.
